Blog · Evidence, in plain language

Negative symptoms: the work your room already does, tested in an app.

A patient with schizophrenia may tell you their prescriber has offered them an app for low motivation and withdrawal. That offer now rests on a phase 3 trial, published in JAMA Network Open in September 2026, and an FDA clearance announced in October 2026. This post sets out what the trial actually tested, what its result can and cannot support, and which parts of a plan like this sit in your room and which sit with the prescriber.

By Karel Winner, DNP, PMHNP-BC · Published October 27, 2026

This post is professional education, not clinical guidance for an individual patient. It summarizes a published trial and a regulator decision. Prescribing decisions belong to the patient and the prescriber.

What the trial tested

Negative symptoms are the subtractive symptoms of schizophrenia: avolition, anhedonia, and asociality, along with flattened expression and reduced speech. The trial paper states that no FDA-approved medicine is specifically indicated for them, and that drug approaches to the motivation and pleasure symptoms have been ineffective. CONVOKE randomized 457 adults at 66 United States sites, all stable on antipsychotic medication and all with moderate to severe motivation and pleasure symptoms, to the smartphone program CT-155 or to a control app with educational content, for 16 weeks. The program packages techniques therapists will recognize: adaptive goal setting, cognitive restructuring aimed at defeatist beliefs, social skills training, positive affect work, and distress tolerance skills. Neither participants nor the clinicians rating symptoms knew which app each person had.

On the main measure, motivation and pleasure symptoms improved 6.8 points in the program group and 4.2 points in the control group. The 2.6 point difference was statistically significant, with an effect size of 0.36, which the authors call small to moderate and comparable to in-person psychosocial treatment. Participants used the program almost 45 minutes a week, and 70.4 percent stayed active through week 15. Serious adverse events were reported by 1.3 percent of the program group and 2.2 percent of the control group, none judged related to treatment. The FDA clearance, announced October 5, 2026, names the product Motivista and limits it to an adjunct role: alongside clinician-managed outpatient care including antipsychotic therapy, in adults whose positive symptoms are clinically stable. The clearance announcement calls the result a 62 percent relative improvement. That is the same 2.6 points expressed against the control group's change, and the plainer figure is the one to quote to a patient.

What belongs in the therapy room

Start with the boundary the trial itself draws: people receiving psychotherapy were excluded, so this study cannot say the program matches, beats, or adds to a therapist's work. What it does support is that the techniques themselves, goal setting, work on defeatist beliefs, social practice, carry measurable effect on these symptoms. If a patient is using the program, the material it generates is session material. Which goals stuck, which collapsed, what the patient attempted socially or recreationally between sessions: the trial found its gains concentrated in exactly those two areas, social and recreational functioning, so change there is worth noticing and naming carefully rather than praising past its size.

Observation is also yours. Work and school functioning did not meaningfully separate between groups, expressive symptoms did not significantly improve, and patients' own overall ratings were no longer significantly different at week 16. A patient who reports trying hard and feeling no different is describing a pattern the data contains, not failing the treatment. Helping them report that pattern precisely, what changed, what did not, and over what period, gives the prescriber the information a decision about continuing the program has to rest on. Flat or worsening presentation, new withdrawal, or any safety concern should reach the prescriber promptly, in specific terms.

What belongs to the prescriber

This is a prescription product with a bounded indication. Whether a patient is stable enough to fit it, whether it sits sensibly alongside their antipsychotic regimen, and whether it continues after the trial-length period are prescribing judgments, and they are not settled in the therapy room. The same holds for any question about changing medication because an app has been added: the trial kept everyone on stable medication throughout, so it offers no support at all for reducing or stopping an antipsychotic. One disclosure point belongs in a therapist's assessment of the evidence: the study was funded by Boehringer Ingelheim, the product was codeveloped by its two sponsoring companies, and several authors are company employees. The design was blinded and randomized, and independent replication has not yet happened. Both halves of that sentence should travel with the result.

Sources

Pratap and colleagues, JAMA Network Open (2026): the CONVOKE trial, a phase 3, double-blind, randomized trial of the smartphone therapeutic CT-155 against a digital control app in 457 adults with negative symptoms of schizophrenia, run at 66 sites in the United States. JAMA Network Open.

ClinicalTrials.gov record NCT05838625: the registered CONVOKE study, its design, its eligibility rules, and its primary outcome measure. ClinicalTrials.gov record.

Click Therapeutics announcement, October 5, 2026: the FDA granted 510(k) clearance to Motivista (CT-155) for the treatment of negative symptoms of schizophrenia, as an adjunct to clinician-managed outpatient care including antipsychotic therapy, in patients 18 years of age and older with clinically stable positive symptoms. FDA clearance announcement.

If a patient is having thoughts of harming themselves, the crisis standard applies: call or text 988, text HOME to 741741 for Crisis Text Line, or call the NAMI Helpline at 1-800-950-6264. This practice is not an emergency service.